Literature DB >> 25492487

Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma.

Rong-Rong Song1, Xiao-Lin Gu.   

Abstract

The aim of the meta-analysis described below was to investigate the correlation between serum levels of adiponectin (ADPN) and the pathogenesis of hepatocellular carcinoma (HCC). Relevant studies about serum ADPN levels and the pathogenesis of HCC were identified by searching electric databases and by manual search. The included studies were selected in strict accordance with the inclusion and exclusion criteria. Detailed criteria were described in "Materials and methods" section. Statistical analyses were conducted with the STATA 12.0 statistical software (StataCorp, College Station, TX, USA). A total of nine studies were incorporated into this meta-analysis after careful consideration, including 705 HCC patients and 1390 healthy controls. This meta-analysis demonstrated that the serum ADPN levels in HCC patients were significantly higher than those in healthy controls (standard mean difference (SMD) = 0.97, 95% confidence intervals (CI) = 0.02∼1.93, P < 0.05). The result of subgroup analysis by ethnicity revealed that serum ADPN levels in Caucasians and Asians were both obviously higher than those in healthy controls (Caucasians: SMD = 0.51, 95% CI = 0.30∼0.73, P < 0.001; Asians: SMD = 0.49, 95% CI = 0.06∼0.91, P < 0.05), but in Africans, the differences between HCC patients and controls had no statistical significance (SMD = 2.64, 95% CI = -3.01∼8.30, P = 0.36). The evidence obtained by this meta-analysis suggests that serum ADPN levels are associated with the pathogenesis of HCC. Further conclusion might be that increased serum levels of ADPN can inhibit tumor growth and play a protective role in the development of HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25492487     DOI: 10.1007/s13277-014-2931-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  43 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Insulin-like growth factor binding protein control secretion and mechanisms of action.

Authors:  D R Clemmons
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

3.   Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma.

Authors:  Mahmoud A Khattab; Mohammed Eslam; Yousef I Mousa; Nosa Ela-adawy; Shimaa Fathy; Mohammed Shatat; Hesham Abd-Aalhalim; Amal Kamal; Mohammed A Sharawe
Journal:  Ann Hepatol       Date:  2012 Jul-Aug       Impact factor: 2.400

4.  Adiponectin and adiponectin receptor in relation to colorectal cancer progression.

Authors:  Jeong-Sik Byeon; Jin-Yong Jeong; Mi Jung Kim; Sun-Mi Lee; Won-Hee Nam; Seung-Jae Myung; Jae Gyu Kim; Suk-Kyun Yang; Jin-Ho Kim; Dong Jin Suh
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

5.  Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C.

Authors:  Nobuyoshi Fukushima; Ryoko Kuromatsu; Teruko Arinaga-Hino; Eiji Ando; Akio Takata; Shuji Sumie; Masahito Nakano; Takumi Kawaguchi; Tatsuya Ide; Takuji Torimura; Michio Sata
Journal:  Hepatol Res       Date:  2010-09       Impact factor: 4.288

Review 6.  Adiponectin action from head to toe.

Authors:  Karine Brochu-Gaudreau; Charlotte Rehfeldt; Richard Blouin; V Bordignon; Bruce D Murphy; Marie-France Palin
Journal:  Endocrine       Date:  2009-12-01       Impact factor: 3.633

7.  Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway.

Authors:  Michiko Sugiyama; Hirokazu Takahashi; Kunihiro Hosono; Hiroki Endo; Shingo Kato; Kyoko Yoneda; Yuichi Nozaki; Koji Fujita; Masato Yoneda; Koichiro Wada; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Int J Oncol       Date:  2009-02       Impact factor: 5.650

8.  Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice.

Authors:  Tamao Nishihara; Miyako Baba; Morihiro Matsuda; Masahiro Inoue; Yasuko Nishizawa; Atsunori Fukuhara; Hiroshi Araki; Shinji Kihara; Tohru Funahashi; Shinji Tamura; Norio Hayashi; Hiroyasu Iishi; Iichiro Shimomura
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

9.  Acute pancreatitis and obstructive jaundice as initial complaints of hepatocellular carcinoma: case report.

Authors:  Guo-Qing Jiang; Jian-Jun Qian; Jie Yao; Sheng-Jie Jin; Dou-Sheng Bai
Journal:  World J Surg Oncol       Date:  2014-01-14       Impact factor: 2.754

10.  Simulating photon scattering effects in structurally detailed ventricular models using a Monte Carlo approach.

Authors:  Martin J Bishop; Gernot Plank
Journal:  Front Physiol       Date:  2014-09-09       Impact factor: 4.566

View more
  4 in total

1.  Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.

Authors:  Jing Shen; Chih-Ching Yeh; Qiao Wang; Irina Gurvich; Abby B Siegel; Regina M Santella
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

2.  The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis.

Authors:  Lilong Zhang; Qihang Yuan; Man Li; Dongqi Chai; Wenhong Deng; Weixing Wang
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

3.  Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Gian Paolo Caviglia; Angelo Armandi; Chiara Rosso; Silvia Gaia; Serena Aneli; Emanuela Rolle; Maria Lorena Abate; Antonella Olivero; Aurora Nicolosi; Marta Guariglia; Davide Giuseppe Ribaldone; Patrizia Carucci; Giorgio Maria Saracco; Elisabetta Bugianesi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

4.  Adiponectin is associated with poor prognosis in carcinoma patients: evidence from a meta-analysis.

Authors:  Jiaxiang Ye; Zhongguo Liang; Qian Liang; Jinyan Zhang; Sufei Mao; Rui Liang
Journal:  Lipids Health Dis       Date:  2015-11-26       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.